"Immunotherapy, Adoptive" - Books

Result Filters

Results: 1 to 20 of 74 books (591 items)

<< First< Prev

Page of 4

Next >Last >>

Select item 49075341.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1c.)

Top results in this book Table of Contents

Select item 48848122.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1e.)

Top results in this book Table of Contents

Select item 48845143.

Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1d.)

Top results in this book Table of Contents

Select item 48849384.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health Technology Assessment Introduction and Clinical Review Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. (CADTH Optimal Use Report, No. 9.1a.)

Top results in this book Table of Contents

Select item 47615565.

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical Section [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. (CADTH Optimal Use Report, No. 8.3a.)

Top results in this book Table of Contents

Select item 47617946.

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics Section [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep. (CADTH Optimal Use Report, No. 8.3b.)

Top results in this book Table of Contents

Select item 16686907.

Holland-Frei Cancer Medicine. 6th edition.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.

Hamilton (ON): BC Decker; 2003.

Top results in this book Table of Contents

Select item 23639748.

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.

Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors.

Cambridge: Cambridge University Press; 2007.

Top results in this book Table of Contents

Select item 48850009.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1f.)

Top results in this book Table of Contents

Select item 488464010.

Axicabtagene Ciloleucel for Large B-cell Lymphoma: Implementation and Ethics Project Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. (CADTH Optimal Use Report, No. 9.1b.)

Top results in this book Table of Contents

Select item 568529611.

The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition.

Sureda A, Corbacioglu S, Greco R, et al., editors.

Cham (CH): Springer; 2024.

Top results in this book Table of Contents

Select item 265918212.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 141528013.

Madame Curie Bioscience Database [Internet].

Austin (TX): Landes Bioscience; 2000-2013.

Top results in this book Table of Contents

Select item 165410614.

Immunobiology: The Immune System in Health and Disease. 5th edition.

Janeway CA Jr, Travers P, Walport M, et al.

New York: Garland Science; 2001.

Top results in this book Table of Contents

Select item 440366815.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

Top results in this book Table of Contents

Select item 428975416.

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop.

National Cancer Policy Forum; Board on Health Care Services; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine.

Washington (DC): National Academies Press (US); 2016 Oct 11.

Top results in this book Table of Contents

Select item 282152417.

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Top results in this book Table of Contents

Select item 538883418.

Ovarian Cancer [Internet].

Lele S, editor.

Brisbane (AU): Exon Publications; 2022 Sep 8.

Top results in this book Table of Contents

Select item 456572819.

Drugs and Lactation Database (LactMed®) [Internet].

Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Top results in this book Table of Contents

Select item 493301220.

Hepatocellular Carcinoma: Translational Precision Medicine Approaches [Internet].

Hoshida Y, editor.

Cham (CH): Humana Press; 2019.

Top results in this book Table of Contents

<< First< Prev

Page of 4

Next >Last >>

Supplemental Content

Images search in Bookshelf

FIGURE 2-2

Adoptive cellular therapy. T cells or tumor infiltrating lymphocytes are removed from a cancer patient and activated and expanded. These activated T cells and tumor infiltrating lymphocytes are then returned to the patient after patient treatment with chemotherapy, and in some cases radiotherapy, and/or hematopoietic stem cell transplantation.
NOTE: HSC = hematopoietic stem cells; PBMC = peripheral blood mononuclear cell; TIL = tumor infiltrating lymphocytes.
SOURCES: June presentation (June 13, 2011) and Grupp and June, 2011. With kind permission from Springer Science+Business Media: Cancer Immunology and Immunotherapy, Adoptive cellular therapy, 2011, 151, S. A. Grupp and C. H. June, Figure 1.

Why Combinations and Collaborations Are Necessary.

National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine. Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary. Washington (DC): National Academies Press (US); 2011 Oct 31.
FIGURE WO-19Adoptive T-cell immunotherapy

Cells are extracted from a cancer patient, and then genetically engineered to express a specific T-cell receptor (TCR) against a specific peptide/major histocompatibility complex (p/MHC) antigen, called the MART-1 antigen, that is on the surface of melanoma tumors. The engineered cells are expanded to ~10⁹ cells and then reintroduced back into the patient. The data shown are flow cytometry data of CD3+ T-cells, from patient F5-1, before and after the genetic engineering process that makes them MART-1 antigen–specific. The MART-1 antigen is associated with the heavy pigmentation of melanoma tumors. At right are presented PET scans from a melanoma cancer patient participating in the immunotherapy trial. The patient exhibits a significant positive response by day 30. For the PET scan corresponding to 30 days after infusion of the engineered T-cells, most of the metabolic activity in the metastatic tumors has decreased. The brain, the bladder, and the kidneys continue to appear dark due to the clearance of fluorodeoxyglucose (FDG) through those organs.
SOURCE: Heath (2011).

Workshop Overview.

Institute of Medicine (US) Forum on Microbial Threats. The Science and Applications of Synthetic and Systems Biology: Workshop Summary. Washington (DC): National Academies Press (US); 2011.
Fig. 74.2

Generation of antigen-specific T-cells.

Adoptive immunotherapy for herpesviruses.

Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
Fig. 74.1

Generation of cell-mediated immune response. See (color plate section.)

Adoptive immunotherapy for herpesviruses.

Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007.